Dual tumor-associated antigens (Dual TAA)

Dual tumor-associated antigens (TAAs) on metastatic castration-resistant prostate cancer (mCRPC) cells represent a therapeutic strategy involving the simultaneous targeting of two different cell-surface proteins to improve treatment efficacy and specificity (Huang et al., 2020). This approach addresses the challenge of intra-tumoral heterogeneity and antigen escape, which are common in advanced prostate cancer treated with single-antigen therapies like those targeting Prostate-Specific Membrane Antigen (PSMA) (Zarrabi et al., 2023). By utilizing bispecific antibodies, bispecific antibody-drug conjugates (ADCs), or dual-targeted CAR-T cells, researchers aim to target antigen pairs such as PSMA and Six-Transmembrane Epithelial Antigen of the Prostate 1 (STEAP1), Prostate Stem Cell Antigen (PSCA), or Human Kallikrein 2 (hK2) (PatSnap, 2026; Narayan et al., 2022). These dual-targeting agents can enhance tumor selectivity by requiring the presence of both antigens for activation or by ensuring that tumor cells expressing either antigen are effectively eliminated (Huang et al., 2020). This strategy is particularly relevant in the context of mCRPC, where tumors often exhibit varying levels of antigen expression and can develop resistance to conventional therapies (DelveInsight, 2023).

Other names

Dual-antigen targetingCo-targeted tumor antigensBispecific tumor-associated antigensDual TAA targeting

Simultaneous binding of two distinct tumor-associated antigens to enhance selectivity, overcome tumor heterogeneity, and prevent antigen escape (Huang et al., 2020; PatSnap, 2026).